Thomas C. Chen MD
Brain & Spinal Tumor, Neurosurgical Spine Surgery
Professor, neurosurgery and pathology Director USC Brain and Spine Tumor Center
Join to View Full Profile
1520 San Pablo StSte 3800Los Angeles, CA 90033
Phone+1 323-442-5720
Fax+1 323-442-7543
Dr. Chen is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Thomas Chen is a neurosurgeon based in Los Angeles, CA, specializing in brain and spinal tumors and neurosurgical spine surgery. He completed his medical education at the University of California San Francisco and neurosurgical residencies at USC/LA General and the Medical College of Wisconsin. Since 1997, Dr. Chen has held multiple roles, including professor at the Los Angeles General Medical Center and mentor roles at the Keck School of Medicine. He is experienced in neurosurgical oncology and spine surgeries, and has authored several publications on innovative therapeutic approaches. Dr. Chen has been recognized by Castle Connolly as one of America's Top Doctors. His involvement in clinical trials includes research on treating metastatic spine cancer and glioblastoma multiforme. Dr Chen is the founder and CMO, CSO of NeOnc Technologies (NTHI) a Global Nasdaq biotechnology company focused on novel delivery and synthesis of new therapies for brain cancer.
Education & Training
Medical College of Wisconsin Affiliated HospitalsResidency, Neurological Surgery, 1996 - 1997
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Neurological Surgery, 1988 - 1995
University of California San Francisco School of MedicineClass of 1988
University of Illinois, Urbana-ChampaignB.S., Summa Cum Laude, 1984
Certifications & Licensure
AZ State Medical License 1974 - Present
CA State Medical License 1989 - 2027
ND State Medical License 1999 - 2002
WI State Medical License 1996 - 1997
American Board of Neurological Surgery Neurological Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2015, 2017
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2015, 2017
- CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2015, 2017
Clinical Trials
- Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
- Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma.Thomas C Chen, Steve Swenson, Thu Zan Thein, Radu O Minea, Axel H Schönthal
Veterinary and Comparative Oncology. 2025-09-01 - Patient with recurrent grade 4 astrocytoma responding favorably to intranasal delivery of NEO100, highly pure perillyl alcohol: illustrative case.Axel H Schönthal, Stephen Swenson, Frank M Senecal, Rhonda Mittenzwei, John L Go
Journal of Neurosurgery. Case Lessons. 2025-03-17 - 5 citationsBringing intranasal drug delivery for malignancies in the brain to market.Thomas C Chen, Clovis O da Fonseca, Axel H Schönthal
Expert Opinion on Drug Delivery. 2025-03-01
Journal Articles
- Convection Enhanced Delivery of Bevacizumab Prolongs Survival of Glioma-bearing Animals Compared to Systemic DeliveryWang W, Sivakumar W, Torres S, Jhaveri N, Vaikari WP, Gong A, Howard A, Golden EB, Louie SG, Schonthal AH, Hofman FM, Chen TC, Focus, 1/1/2015
- Quinoline-based antimalarial drugs: a novel class of autophagy inhibitorsGolden EB, Cho HY, Hofman FM, Louie SB, Schonthal AH, Chen TC, Focus, 1/1/2015
- A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivoChen TC, Cho HY, Wang W, Nguyen J, Jhaveri N, Rosenstein-Sisson R, Hofman FM,Schonthal AH, Cancer Letters, 1/1/2015
Books/Book Chapters
Abstracts/Posters
- Metronomic biofeedback pump and the vision of local deliveryChen TC, Case Western Reserve, 1/30/2015
- NEO212: A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against temozolomide resistant gliomas and intracranial triple negative breast cance...Chen TC, Asilomar, 1/22/2014
- C2 fracture/odontoidChen TC, AO Spine, Davos, Switzerland, 1/14/2014
Press Mentions
Revolutionizing Biotech: How NeOnc Technologies Is Striving to Transform Brain Cancer Treatment and Drive Industry InnovationJanuary 13th, 2025- USC Brain Tumor Center’s Scientific Director Receives $50,000 Award for Brain Cancer ResearchMay 1st, 2023
Good Samaritan Hospital, USC Keck School of Medicine Affiliate for Neurosurgical CareFebruary 12th, 2016
Grant Support
- A novel brachytherapy agent for GBMNIH2013–2015
Professional Memberships
- Member
- Fellow
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
